[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Bhattacharya A, Tóth K, Mazurchuk R, Spernyak JA, Slocum HK, Pendyala L, Azrak R, Cao S, Durrani FA, Rustum YM: Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clin Cancer Res; 2004 Dec 1;10(23):8005-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
  • PURPOSE: Combination chemotherapy with irinotecan (CPT-11; 50 mg/kg/week x 4 intravenously), followed 24 hour later by 5-fluorouracil (50 mg/kg/week x 4 intravenously), results in 10 and 100% cure rates of animals bearing human head and neck squamous cell carcinoma xenografts A253 and FaDu, respectively.
  • A253 consists of 30% well-differentiated and avascular and 70% poorly differentiated regions with low microvessel density (10/x400), whereas FaDu is uniformly poorly differentiated with higher microvessel density (19/x400).
  • Studies were carried out for determining the role of well-differentiated and avascular regions in drug resistance in A253 and detection of such regions with noninvasive functional magnetic resonance (fMR) imaging.
  • EXPERIMENTAL DESIGN: Tumors were harvested for histopathologic evaluation and immunohistochemistry (CD31, CD34; differentiation marker: involucrin; hypoxia markers: carbonic anhydrase IX, pimonidazole; vascular endothelial factor (VEGF) and Ki67) immediately after fMR imaging following the 3rd dose of chemotherapy.
  • High-performance liquid chromatography determination of intratumoral drug concentration of 7-ethyl-10-hydroxyl-camptothecin and autoradiography with (14)C-labeled CPT-11 was done 2 hours after CPT-11 administration.
  • RESULTS: Although A253 xenografts showed three times higher concentration of 7-ethyl-10-hydroxyl-camptothecin, FaDu was more responsive to therapy.
  • After therapy, A253 tumor consisted mostly (approximately 80%) of well-differentiated regions (positive for involucrin) lacking microvessels with a hypoxic rim (positive for carbonic anhydrase IX and pimonidazole) containing few proliferating (Ki67 positive) poorly differentiated cells.
  • Autoradiography revealed that well-differentiated A253 tumor regions showed 5-fold lower (14)C-labeled CPT-11 concentrations compared with poorly differentiated areas (P < 0.001).
  • CONCLUSION: Avascular-differentiated regions in squamous cell carcinoma offer sanctuary to some hypoxic but viable tumor cells (carbonic anhydrase IX and Ki67 positive) that escape therapy because of limited drug delivery.
  • This study provides direct evidence that because of a specific histologic structure, avascular, well-differentiated hypoxic regions in tumors exhibit low drug uptake and represent a unique form of drug resistance.
  • [MeSH-major] Anoxia. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Squamous Cell / drug therapy. Cell Differentiation. Drug Resistance, Neoplasm. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Drug Delivery Systems. Female. Fluorouracil / administration & dosage. Humans. Magnetic Resonance Imaging. Mice. Mice, Nude. Microcirculation. Oxygen / blood. Rats. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15585636.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16056
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 7673326042 / irinotecan; S88TT14065 / Oxygen; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


2. Thariat J, Ahamad A, El-Naggar AK, Williams MD, Holsinger FC, Glisson BS, Allen PK, Morrison WH, Weber RS, Ang KK, Garden AS: Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer; 2008 Jun 15;112(12):2698-709
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study.
  • BACKGROUND: Basaloid squamous cell carcinoma (BSCC) is an uncommon, high-grade variant of squamous cell carcinoma (SCC) of the head and neck.
  • METHODS: From 1994 to 2004, 1007 patients received radiotherapy for head and neck carcinoma with lymph node involvement.
  • The histologic types consisted of 51 BSCC, 431 poorly differentiated SCC (PSCC), and 525 well or moderately differentiated SCC (WMSCC).
  • RESULTS: Patients with BSCC received treatment modalities similar to those received by patients with SCC: They received induction chemotherapy (12%) or concurrent chemotherapy (33%), and a median radiation dose of 70 Gray.
  • On the basis of the high rate of lung metastases and the possibility of efficient salvage, the authors recommend obtaining a chest computed tomography scan during initial staging and follow-up.
  • [MeSH-major] Carcinoma, Basosquamous / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local. Prognosis. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18429002.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA06294
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Farhat FS, Geara F, Natout M, Serhal J, Daya W: Tongue carcinoma in an adult Down's syndrome patient: a case report. World J Surg Oncol; 2009;7:26
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tongue carcinoma in an adult Down's syndrome patient: a case report.
  • CASE PRESENTATION: This case report describes a 27 years old male with Down's syndrome, non-smoker, who developed a poorly differentiated squamous cell carcinoma of the tongue.
  • The patient underwent a hemiglossectomy without neck dissection followed by a postoperative locoregional radiation therapy to a total tumor-bed dose of 56 Gy and 45 Gy to the neck.
  • Three months later, the patient presented with local tongue recurrence and was treated by Docetaxel and Carboplatin chemotherapy with no significant response.
  • CONCLUSION: To our knowledge, this is the first case of tongue carcinoma arising in a patient with Down's syndrome.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Down Syndrome / complications. Tongue Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • [Cites] Lancet Oncol. 2001 Jul;2(7):429-36 [11905737.001]
  • [Cites] Int J Cancer. 2002 Sep 1;101(1):95-9 [12209594.001]
  • [Cites] Pediatrics. 1970 Jan;45(1):60-70 [4243491.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):993-9 [2069856.001]
  • [Cites] Semin Cancer Biol. 2008 Oct;18(5):365-71 [18455928.001]
  • [Cites] Head Neck. 1994 Mar-Apr;16(2):107-11 [8021128.001]
  • [Cites] Med Pediatr Oncol. 1995 May;24(5):305-9 [7700182.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):448-52 [9458088.001]
  • [Cites] Oncol Rep. 1999 Nov-Dec;6(6):1223-7 [10523685.001]
  • [Cites] Nature. 2008 Jan 3;451(7174):21-2 [18172483.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):3-11 [8482629.001]
  • (PMID = 19261193.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2664806
  •  go-up   go-down


Advertisement
4. Taguchi T, Tsukuda M, Mikami Y, Matsuda H, Tanigaki Y, Horiuchi C, Nishimura G, Nagao J: Treatment results and prognostic factors for advanced squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Auris Nasus Larynx; 2009 Apr;36(2):199-204
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results and prognostic factors for advanced squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy.
  • OBJECTIVE: To review our experience in the treatment of concurrent chemoradiotherapy (CCR) for patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and to evaluate the different factors affecting survival and primary organ preservation.
  • CONCLUSION: In the treatment of CCR for advanced SCCHN, the survival rate of the patients with resectable tumors was excellent and significantly greater compared with the patients with unresectable tumors.
  • CCR may improve not only primary organ preservation (local control) but also survival in patients with poorly differentiated tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Otorhinolaryngologic Neoplasms / drug therapy. Otorhinolaryngologic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632233.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


5. Tian WD, Zeng ZY, Yu WB, Li XP: [Application of SELDI-TOF-MS in establishing a model for predicting radiotherapy response of hypopharyngeal cancers]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun;30(6):1282-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To detect the serum proteomic fingerprints in patients with hypopharyngeal squamous cell carcinoma (HPSCC) by surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) protein chip array technique.
  • RESULTS: The protein profiles of HPSCC serum were analyzed according to the clinical and pathological features of the patients and their treatment response.
  • No significant difference was noted in the serum proteins between HPSCC patients with different statuses of cervical lympha node metastasis (P>0.05), and the difference between well differentiated and poorly differentiated HPSCC was only minor.
  • No significant difference was found in the serum proteins between chemotherapy-sensitive patients and the insensitive patients (P>0.05), but 5 proteins were identified to be overexpressed in the sensitive patients (P < / = 0.05).
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / radiotherapy. Proteome / analysis. Radiation Tolerance. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584658.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  •  go-up   go-down


6. Kawecki A, Jagielska B, Jarzabski A, Szutkowski Z, Kiprian D, Rolski W, Pawłowska-Sendułka B: [Concomitant radiochemotherapy followed by adjuvant chemotherapy in patients with poorly differentiated nasopharyngeal cancer; tolerance and early results of treatment]. Otolaryngol Pol; 2005;59(5):671-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concomitant radiochemotherapy followed by adjuvant chemotherapy in patients with poorly differentiated nasopharyngeal cancer; tolerance and early results of treatment].
  • INTRODUCTION: Recently, concomitant radiochemotherapy became a method of choice in patients with poorly differentiated nasopharyngeal cancer.
  • The aim of this study is to estimate tolerance and early results of the concomitant radiochemotherapy followed by adjuvant chemotherapy (modified US Head and Neck Intergroup protocol).
  • METHODS AND MATERIAL: Analysing protocol consist of conventionally fractionated radiotherapy (TD = 70 Gy) given concomitantly with cisplatin (30 mg/m2 daily during 3 days every 3 weeks).
  • This part of treatment was followed by 3 courses of PF (cisplatin + 5-fluorouracil) chemotherapy.
  • Between August 1998 and September 2003 thirty six patients (27 male and 9 female) were qualified to treatment.
  • Tolerance of the adjuvant chemotherapy was worse.
  • Only 44% patients received all three courses of PF chemotherapy.
  • The reasons of incomplete chemotherapy were neutropenia, infections, prolongated acute reactions or performance status decreasing.
  • CONCLUSIONS: Our results confirm high activity of the concomitant radiochemotherapy followed by chemotherapy in patients with poorly differentiated nasopharyngeal cancer.
  • Those results confirm also high toxicity of this regimen, what suggest very careful patients qualification to treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471182.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Larsen CR, Hansen PB, Clausen NT: Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues. Am J Hematol; 2002 May;70(1):48-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues.
  • Two patients, one with B-cell chronic lymphocytic leukemia (CLL) and one with hairy-cell leukemia (HCL), were treated with immunosuppressive chemotherapy.
  • The patient with CLL was a 54-year-old female, who had had a squamous cell carcinoma (SCC) excised from her forehead 5 months before receiving the first course of fludarabine.
  • During the fludarabine treatment, the patient developed a local SCC relapse and metastases in the neck.
  • The carcinoma was treated by excision and radiotherapy, and further fludarabine treatment was withheld.
  • Nevertheless, the SCC metastasized aggressively and the patient died 3 months after the start of fludarabine treatment, primarily due to respiratory failure.
  • At the time of diagnosis of HCL, the patient had two solid tumors in the liver containing poorly differentiated epithelial carcinoma cells of unknown origin.
  • During treatment with 2-chlorodeoxyadenosine (2CdA), the tumors in the liver rapidly spread in multiple intrahepatic metastases, followed by liver failure and death within 1 month.
  • Fludarabine and 2CdA cause a substantial suppression of all lymphocyte subsets, in particular the T-cell line.
  • It is therefore assumed that fludarabine and 2CdA in these two cases triggered an exacerbation of both tumors due to the T-cell depletion.
  • [MeSH-major] 2-Chloroadenosine / therapeutic use. Antineoplastic Agents / therapeutic use. Immunosuppressive Agents / therapeutic use. Leukemia, Hairy Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Liver Neoplasms / drug therapy. Nucleosides / therapeutic use. Vidarabine / therapeutic use
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Multiple Primary. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11994981.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Nucleosides; 146-77-0 / 2-Chloroadenosine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


8. Kaminagakura E, Vartanian JG, da Silva SD, dos Santos CR, Kowalski LP: Case-control study on prognostic factors in oral squamous cell carcinoma in young patients. Head Neck; 2010 Nov;32(11):1460-6
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-control study on prognostic factors in oral squamous cell carcinoma in young patients.
  • BACKGROUND: Oral squamous cell carcinoma affects mainly patients between the fifth and sixth decades of life, being rare in the young (≤40 years old).
  • In the younger patients, tumors at advanced clinical stage (p < .01) and poorly differentiated tumors (p = .01) were associated with a higher risk of recurrence.
  • The younger patients diagnosed after the 1990s had less advanced clinical stage tumors, had an increase in the use of combination of surgery, radiotherapy, and chemotherapy, and their overall survival was improved.
  • CONCLUSION: This study emphasizes the importance of early diagnosis and aggressive treatment of oral squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Mouth Neoplasms / mortality. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Brazil / epidemiology. Case-Control Studies. Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Middle Aged. Neck Dissection. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Smoking / epidemiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20175200.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Paulino AF, Singh B, Carew J, Shah JP, Huvos AG: Epstein-Barr virus in squamous carcinoma of the anterior nasal cavity. Ann Diagn Pathol; 2000 Feb;4(1):7-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus in squamous carcinoma of the anterior nasal cavity.
  • Squamous carcinoma is the most common malignancy of the head and neck, but it rarely occurs in the nasal vestibule.
  • Epstein-Barr virus (EBV) has been detected in and is causally linked to various head and neck tumors, particularly nasopharyngeal carcinoma.
  • The possible role of EBV in squamous carcinoma of the anterior nasal cavity, particularly of the nasal vestibule, has not been previously investigated.
  • Histologic sections from 17 patients with nasal vestibular squamous carcinoma were examined.
  • Material for EBV detection by immunohistochemistry and by in situ hybridization was available in 15 of the 17 cases.
  • The squamous carcinomas were graded as well differentiated (one case), moderately differentiated (11 cases), and poorly differentiated (five cases).
  • Treatment modalities included surgical resection, radiation, chemotherapy, or a combined approach.
  • Three patients developed metastases, one of whom died of disease after 1 year.
  • Squamous carcinoma of the nasal vestibule is an uncommon cancer that is not causally related to EBV.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Herpesvirus 4, Human / isolation & purification. Nasal Cavity / virology. Nose Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10684374.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


10. McLaughlin PJ, Stack BC Jr, Braine KM, Ruda JD, Zagon IS: Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration. Int J Oncol; 2004 Jan;24(1):227-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration.
  • Opioid growth factor (OGF), [Met5]-enkephalin, interacts with the OGF receptor (OGFr) to inhibit the growth of human squamous cell carcinoma of the head and neck (SCCHN) in vitro.
  • Administration of OGF by daily intraperitoneal injection (i.p.) to animals with xenografts of CAL-27, a poorly differentiated SCCHN, is known to repress tumorigenic events.
  • In this study, the ubiquity of OGF action on SCCHN was investigated by examination of OGF activity on SCC-1 tumors; this human cell line is well-differentiated and highly invasive.
  • These data indicate that: i) the inhibitory action of OGF may be ubiquitous for SCCHN, ii) OGF treatment alters the characteristics of the OGF receptor but not of plasma OGF levels, and iii) the magnitude of effects of OGF on SCCHN is dependent on the route of administration.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Enkephalin, Methionine / pharmacology. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Animals. Body Weight / drug effects. Cell Division / drug effects. Humans. Infusion Pumps. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Random Allocation. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14654962.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 58569-55-4 / Enkephalin, Methionine
  •  go-up   go-down


11. Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M, Lavertu P, Lorenz RR, Carroll MA: Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol; 2006 Mar 1;24(7):1064-71
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
  • PURPOSE: A retrospective review with long-term follow-up is reported from the Cleveland Clinic Foundation studying radiation and concurrent multiagent chemotherapy in patients with locoregionally advanced squamous cell head and neck cancer.
  • PATIENTS AND METHODS: Between 1989 and 2002, 222 patients were treated with 4-day continuous infusions of fluorouracil (1,000 mg/m2/d) and cisplatin (20 mg/m2/d) during weeks 1 and 4 of either once daily or twice daily radiation therapy.
  • Including patients undergoing primary site resection as salvage therapy, the overall local control rate is 92.4%.
  • Distant control at 5 years was achieved in 85.4% of patients and was significantly worse in patients with hypopharyngeal primary sites and patients with poorly differentiated tumors.
  • CONCLUSION: Concurrent multiagent chemoradiotherapy can result in organ preservation and cure in the majority of appropriately selected patients with locoregionally advanced, nonmetastatic, squamous cell head and neck cancer.
  • Distant metastatic disease was the most common cause of treatment failure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Mar 1;24(7):1023-5 [16505419.001]
  • (PMID = 16505425.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Wang X, Xie FY, Han F, Hu WH, Li JS, Xu HM: [Tonsillar carcinoma: analyses of the therapy and prognostic factors]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Oct;44(10):848-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tonsillar carcinoma: analyses of the therapy and prognostic factors].
  • OBJECTIVE: To retrospectively analyze the therapeutic effect on patients with tonsillar carcinoma and factors affecting their prognosis.
  • METHODS: Clinical data of 61 patients pathologically confirmed with tonsillar carcinoma without distant metastasis were analyzed.
  • There were 2 patients with undifferentiated carcinoma, 26 with poorly differentiated squamous cell carcinoma and 33 with median-well differentiated squamous cell carcinoma.
  • According to the AJCC 2002 staging criteria for head-neck cancers, there were 9 staged I cases, 7 staged II cases, 23 staged III cases and 22 staged IV cases.
  • The treatment was radiotherapy alone in 27 cases, radiotherapy combined with chemotherapy in 23 cases, surgery combined with postoperative radiotherapy in 6 cases, neoadjuvant chemotherapy plus surgery combined with postoperative radiotherapy in 3 cases, radiotherapy with salvage surgery in 2 cases.
  • The difference between the two treatments was not significant in statistics (P = 0.318).
  • For III-IV staged 45 cases, there were 19 cases with simple radiotherapy, 5 years survival was 51.5%, 21 cases with radiotherapy combined with chemotherapy, 5 years survival was 36.4%, 5 cases with surgery combined with postoperative radiotherapy, 5 years survival was 75.0%.
  • The difference among the three treatments was not significant in statistics (P = 0.239).
  • Multivariate analysis demonstrated that T stage, therapeutic effect of primary site and cervical metastatic lymph node were the independent prognostic factors (P < 0.05).
  • CONCLUSIONS: T stage, the therapeutic effect of primary site and cervical metastatic lymph node were the independent prognostic factors.
  • For III-IV staged cases, yet the relationships between therapeutic mode and therapeutic effect still need further researches.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079056.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Rosati G, Riccardi F, Tucci A: Use of tumor markers in the management of head and neck cancer. Int J Biol Markers; 2000 Apr-Jun;15(2):179-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of tumor markers in the management of head and neck cancer.
  • Serologic tumor markers have been evaluated in the diagnosis, management and follow-up of patients with head and neck cancer.
  • However, to the authors' knowledge no tumor marker has yet been shown to be useful for monitoring the response to chemotherapy in this type of disease, in particular for undifferentiated tumors.
  • The pretreatment levels of CEA, TPA, SCC and ferritin were evaluated in 98 patients with advanced head and neck cancer.
  • Of this group 64 patients were studied sequentially every month during planned chemotherapy and three weeks after treatment using standard commercial kits.
  • In patients with squamous cell cancer SCC and CEA were elevated (by 68% and 54%, respectively) in tumors with good differentiation (G1), but only by 13% (both markers) in tumors classified as poorly differentiated (G3).
  • CEA, SCC and ferritin serum levels were not correlated with response to chemotherapy, while TPA values correlated with the clinical response to treatment in 100% of patients with undifferentiated cancer and in 75% of those with squamous cell cancer.
  • Our data indicate that in patients with head and neck cancer TPA appears to be a sensitive marker, followed in decreasing order of sensitivity by CEA, SCC and ferritin.
  • However, SCC and CEA seem to be the most suitable markers for squamous cell cancer and in particular for more differentiated tumors (G1).
  • Finally, TPA has proved to be a useful marker for monitoring the response to chemotherapy in patients with head and neck cancer, in particular for undifferentiated tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carcinoma / blood. Head and Neck Neoplasms / blood. Immunoradiometric Assay. Neoplasm Proteins / blood. Serpins
  • [MeSH-minor] Antigens, Neoplasm / blood. Carcinoembryonic Antigen / blood. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Case Management. Cell Differentiation. Disease Progression. Female. Ferritins / blood. Follow-Up Studies. Humans. Male. Sensitivity and Specificity. Tissue Polypeptide Antigen / blood. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10883893.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Neoplasm Proteins; 0 / Serpins; 0 / Tissue Polypeptide Antigen; 0 / squamous cell carcinoma-related antigen; 9007-73-2 / Ferritins
  •  go-up   go-down


14. Liu WS, Tang PZ, Qi YF, Xu ZG, Li ZJ: [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Sep;39(9):562-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx].
  • OBJECTIVE: To investigate the clinical characteristics, treatment and prognosis for poorly differentiated supraglottic carcinomas.
  • METHODS: A retrospective study was conducted in 57 cases of poorly differentiated supraglottic carcinomas treated in our hospital from 1980 to 1998.
  • Of the 57 patients, 25 were treated with surgery alone, 9 with irradiation alone, 14 with surgery following preoperative radiation, 7 with postoperative radiation following surgery and 2 with surgery following preoperative chemotherapy.
  • CONCLUSIONS: Poorly differentiated carcinomas of the supraglottic larynx had characteristics of the advanced stage in terms of earlier lymph node metastasis and a relatively high rate of cervical and distant metastasis.
  • Surgery was still the primary treatment for this disease and it was feasible to perform partial laryngectomy on certain patients.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Glottis / surgery. Laryngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606009.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Syrjänen S: The role of human papillomavirus infection in head and neck cancers. Ann Oncol; 2010 Oct;21 Suppl 7:vii243-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of human papillomavirus infection in head and neck cancers.
  • The link between head and neck squamous cell cancer (HNSCC), especially oropharyngeal cancer, and HPV has become established.
  • HPV16 is the most common genotype in these tumours but HPV6 and HPV11 can also be found in a minority of these cancers, implying that these low-risk HPV types are not entirely benign in the head and neck region.
  • HPV DNA is closely associated with poorly differentiated cancers, positive lymph nodes and late-stage disease, which all indicate poor prognosis.
  • Contradictory to this, patients with HPV+ HNSCC seem to have significantly improved response to chemotherapy and radiotherapy as compared with HPV-negative tumours.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20943622.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Papillomavirus Vaccines
  •  go-up   go-down


16. Muramatsu Y, Hasegawa Y, Fukano H, Ogawa T, Namuba M, Mouri K, Fujimoto Y, Matsuura H, Takai Y, Mori M: Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses. Anticancer Res; 2000 Jan-Feb;20(1A):257-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses.
  • Metallothionein (MT), has selectively binding affinity for heavy metal ions and over expression of MT has a potential against resistance for CDDP anticancer agents and radiation treatment.
  • The role of MT immunoreactivity of squamous cell carcinoma in oral and pharyngeal regions (n = 28) and in the maxillary sinus region (n = 3) was evaluated for distribution patterns of MT and clinicopathologic behaviors.
  • MT immunoreactivity was expressed in both tumor cell cytoplasm and nuclei, and showed heterogeneous localization in tumor epithelial cells and in the stroma.
  • In oral and pharyngeal carcinomas (n = 28), MT positive cell index in treated cases (n = 11) was 17.85% and that in non treated tumors (n = 17) was 25.19%.
  • Among histological grading in oral and pharyngeal SCCs, MT index of well differentiated SCC (n = 9) was 17.04%, of moderately differentiated SCC (n = 13) 21.92% and poorly differentiated SCC (n = 6) was 31.06%.
  • [MeSH-major] Carcinoma, Squamous Cell / chemistry. Head and Neck Neoplasms / chemistry. Metallothionein / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / chemistry. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cell Differentiation. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Fluorouracil / administration & dosage. Gingival Neoplasms / chemistry. Gingival Neoplasms / pathology. Gingival Neoplasms / therapy. Humans. Hypopharyngeal Neoplasms / chemistry. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / therapy. Lymphatic Metastasis. Male. Maxillary Sinus Neoplasms / chemistry. Maxillary Sinus Neoplasms / pathology. Maxillary Sinus Neoplasms / therapy. Middle Aged. Mouth Mucosa / chemistry. Tongue Neoplasms / chemistry. Tongue Neoplasms / pathology. Tongue Neoplasms / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10769664.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 9038-94-2 / Metallothionein; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Kawamoto M, Kunisaki C, Kunihiro O, Kamiya N, Moriwaki Y, Akiyama H, Shimada H, Kono N, Nakatani Y, Kunisaki R: Basaloid cell carcinoma of the esophagus with a metastatic neck tumor of unknown origin: report of a case. Surg Today; 2003;33(7):529-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid cell carcinoma of the esophagus with a metastatic neck tumor of unknown origin: report of a case.
  • Aspiration biopsy revealed squamous cell carcinoma (SCC).
  • An endoscopic biopsy was done and the pathological findings indicated poorly differentiated SCC.
  • Histological findings revealed that the tumor in the middle thoracic esophagus was moderately differentiated SCC, and that the other tumor below it was basaloid cell carcinoma (BCC).
  • A diagnosis of poorly differentiated SCC of unknown origin was made for the neck tumor.
  • Postoperative recombinant chemotherapy with cisplatin and 5-fluorouracil was given for the unknown primary site, which we still have not identified.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / pathology. Esophageal Neoplasms / pathology. Head and Neck Neoplasms / secondary. Neoplasms, Unknown Primary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14506999.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Smullen JL, Amedee RG: Sinonasal undifferentiated carcinoma: a review of the literature. J La State Med Soc; 2001 Oct;153(10):487-90
Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal undifferentiated carcinoma: a review of the literature.
  • Sinonasal undifferentiated carcinoma is a relatively rare and aggressive malignancy of the nose and paranasal sinuses.
  • It is often difficult to distinguish from other poorly differentiated sinonasal malignancies.
  • Since it was first described in 1986, advances have been made in the understanding of the histology and immunohistochemical markers of sinonasal undifferentiated carcinoma, but the treatment options and prognosis remain poor.
  • While no treatment is standard for sinonasal undifferentiated carcinoma, several modalities and combinations including chemotherapy, radiation, and surgery have been used with varied success.
  • The several case series reported are examined and future directions of therapy discussed.
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / physiopathology. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / physiopathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18350705.001).
  • [ISSN] 0024-6921
  • [Journal-full-title] The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society
  • [ISO-abbreviation] J La State Med Soc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


19. Yalin Y, Pingzhang T, Smith GI, Ilankovan V: Management and outcome of cervical lymph node metastases of unknown primary sites: a retrospective study. Br J Oral Maxillofac Surg; 2002 Dec;40(6):484-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Poorly differentiated carcinoma was best treated with radiotherapy, squamous cell carcinoma with radiotherapy and excision, and non-papillary adenocarcinoma by radical thyroidectomy and neck dissection.
  • For metastatic masses in the supraclavicular region, chemotherapy was the preferred treatment.
  • [MeSH-major] Carcinoma / secondary. Neoplasms, Unknown Primary / therapy
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Prednisone / administration & dosage. Retrospective Studies. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12464205.001).
  • [ISSN] 0266-4356
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


20. Chung JJ, Namiki T, Johnson DW: Cervical cancer metastasis to the scalp presenting as alopecia neoplastica. Int J Dermatol; 2007 Feb;46(2):188-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 45-year-old Japanese woman was diagnosed in 1996 with squamous cell cancer of the cervix following an abnormal Papanicolaou smear and subsequent diagnostic conization.
  • She underwent total abdominal hysterectomy with pelvic lymphadenectomy and was found to have poorly differentiated squamous cell carcinoma, International Federation of Gynecology and Obstetrics (FIGO) stage IB1.
  • This was confirmed when computerized tomography (CT)-guided lymph node biopsy showed squamous cell carcinoma of the para-aortic lymph nodes histologically consistent with the cervical primary.
  • In addition, there was evidence of lumbar spine metastasis by positron emission tomography (PET) and bone scans.
  • She received several courses of chemotherapy with cisplatin and 5-fluorouracil (5FU), as well as radiation therapy.
  • CT of the abdomen identified widespread metastases in the liver, pancreatic head, and lumbar spine.
  • The patient decided against further treatment for her advanced cervical cancer but did accept hydromorphone for pain.
  • [MeSH-major] Alopecia / etiology. Head and Neck Neoplasms / secondary. Neoplasms, Squamous Cell / secondary. Scalp. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology


21. Yin MB, Li ZR, Tóth K, Cao S, Durrani FA, Hapke G, Bhattacharya A, Azrak RG, Frank C, Rustum YM: Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis. Oncogene; 2006 Apr 20;25(17):2509-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
  • Until recently, the use of Se-methylselenocysteine (MSC) as selective modulator of the antitumor activity and selectivity of anticancer drugs including irinotecan, a topoisomerase I poison, had not been evaluated.
  • Therapeutic synergy between MSC and irinotecan was demonstrated by our laboratory in mice bearing human squamous cell carcinoma of the head and neck tumors.
  • In FaDu xenografts, a poorly differentiated tumor-expressing mutant p53, the cure rate was increased from 30% with irinotecan alone to 100% with the combination of irinotecan and MSC.
  • Cellular exposure to cytotoxic concentration of SN-38, the active metabolite of irinotecan (0.1 microM) alone and in combination with noncytotoxic concentration of MSC (10 microM) did not result in additional enhancement of chk2 phosphorylation and downregulation of specific DNA replication-associated proteins, cdc6, MCM2, cdc25A, nor increase in PARP cleavage, caspase activation and the 30-300 kb DNA fragmentation induced by SN-38 treatment.
  • These results indicate that apoptosis is unlikely to be one of the main mechanism associated with the observed in vivo therapeutic synergy.
  • Analysis of tumor tissues at 24 h after treatment with synergistic modality of irinotecan and MSC revealed significant downregulation of COX-2, inducible nitric oxide synthase (iNOS) and hypoxia-induced factor-1alpha expression (HIF 1alpha).
  • Moreover, decreased microvessel density was observed after irinotecan treatment with the addition of MSC.
  • These results suggest that observed therapeutic synergy correlates with the inhibition of neoangiogenesis through the downregulation of COX-2, iNOS and HIF-1alpha expression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Carcinoma, Squamous Cell / drug therapy. Cyclooxygenase 2 / metabolism. Head and Neck Neoplasms / drug therapy. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Neovascularization, Pathologic / prevention & control. Nitric Oxide Synthase Type II / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cysteine / administration & dosage. Cysteine / analogs & derivatives. Down-Regulation. Female. Humans. Mice. Mice, Nude. Organoselenium Compounds / administration & dosage. Selenocysteine / analogs & derivatives. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. SELENO-(DL)-CYSTEINE .
  • Hazardous Substances Data Bank. CYSTEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518418.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / CA65761
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Organoselenium Compounds; 0CH9049VIS / Selenocysteine; 7673326042 / irinotecan; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2; K848JZ4886 / Cysteine; TWK220499Z / selenomethylselenocysteine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


22. Onn A, Isobe T, Itasaka S, Wu W, O'Reilly MS, Ki Hong W, Fidler IJ, Herbst RS: Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res; 2003 Nov 15;9(15):5532-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.
  • EXPERIMENTAL DESIGN: Human lung adenocarcinoma (PC14PE6), bronchioloalveolar carcinoma (NCI-H358), squamous cell carcinoma (NCI-H226), poorly differentiated non-small cell lung cancer (NCI-H1299 and A549), or small cell lung cancer (NCI-H69) cells in Matrigel were injected percutaneously into the left lungs of nude mice.
  • When the lung cancer cell lines were implanted s.c., systemic therapy with paclitaxel induced tumor regression.
  • However, only a limited therapeutic response to paclitaxel was observed when the same cells were implanted orthotopically into the lung.
  • Immunohistochemical analysis of tumor tissue revealed increased expression of the proangiogenic factors interleukin 8, basic fibroblast growth factor, and vascular endothelial growth factor/vascular permeability factor.
  • CONCLUSIONS: Our orthotopic models of human lung cancer confirm the "seed and soil" concept and likely provide more clinically relevant systems for the study of both non-small cell lung cancer and small cell lung cancer biology, and for characterizing novel therapeutic strategies.
  • [MeSH-major] Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Paclitaxel / therapeutic use
  • [MeSH-minor] Animals. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / physiopathology. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / physiopathology. Cell Line, Tumor. Fibroblast Growth Factor 2 / analysis. Humans. Interleukin-8 / analysis. Lymphatic Metastasis. Mice. Mice, Nude. Models, Biological. Neoplasm Metastasis. Neovascularization, Pathologic / pathology. Vascular Endothelial Growth Factor A / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14654533.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA70907
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Tsou YA, Hua JH, Lin MH, Tsai MH: Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer--does tumor volume correlate with central necrosis and tumor pathology? ORL J Otorhinolaryngol Relat Spec; 2006;68(4):206-12
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer--does tumor volume correlate with central necrosis and tumor pathology?
  • OBJECTIVES: Not all patients with hypopharyngeal cancer who undergo concurrent chemoradiation therapy have a good prognosis.
  • We hope to find the significant prognostic factors that could help us in patient selection for concurrent chemoradiation therapy.
  • STUDY DESIGN: We used a retrospective analysis on several prognostic factors which may affect the treatment outcome and prognosis.
  • METHODS: We studied 51 patients with stage III-IV hypopharyngeal cancer who underwent chemoradiation therapy as the first treatment method.
  • According to the cancer cell differentiation, the hazard risk in the well-differentiated group was 5.62 folds higher than in the poorly differentiated group (p = 0.05).
  • Patients with an initial complete response had a primary tumor volume <19 ml (p = 0.001, 0.016), poorly differentiated pathology (p = 0.001, 0.016), and no central necrosis (p = 0.001, 0.016).
  • CONCLUSION: Tumor volume is the most important prognostic factor of treatment outcome for patients with hypopharyngeal cancer and should always be taken into consideration in treatment planning.
  • Other possible prognostic factors which affect the initial complete response rate and survival rate including central necrosis, pathology, nodal number and nodal volume, T stage above III, and cervical lymphadenopathy beyond level II have a relatively low correlation with treatment outcome.
  • In our study, there was a correlation between tumor volume and central necrosis, but no significant correlation between pathological differentiation and tumor volume, although both affect treatment outcome.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Logistic Models. Lymph Nodes / pathology. Male. Middle Aged. Necrosis. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16508339.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down






Advertisement